IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $53.58.

Several equities research analysts recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Stephens reiterated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in IDYA. Janus Henderson Group PLC boosted its position in shares of IDEAYA Biosciences by 13.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company’s stock valued at $150,606,000 after purchasing an additional 695,263 shares in the last quarter. Norges Bank bought a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at $13,385,000. MPM Bioimpact LLC purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter worth about $10,641,000. FMR LLC grew its position in shares of IDEAYA Biosciences by 2.6% in the 4th quarter. FMR LLC now owns 12,963,151 shares of the company’s stock worth $333,153,000 after buying an additional 327,498 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of IDEAYA Biosciences by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company’s stock worth $130,507,000 after acquiring an additional 282,936 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 5.6 %

IDYA stock opened at $17.08 on Friday. The stock has a market cap of $1.50 billion, a P/E ratio of -5.18 and a beta of 0.51. The stock’s fifty day simple moving average is $18.23 and its two-hundred day simple moving average is $23.80. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. As a group, analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.